anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Tirofiban 5μg/kg was administered intravenously through the catheter artery at a rate of 1ml/min, followed by an intravenous infusion of 0.1μg/(kg·min) for 24 hours. Standard medical treatment was administered after the surgery.
PURPOSE: A complex containing oligo-aspartic acid-PNA for PNA delivery is provided to fuse PNA and oligo aspartic acid(Asp), and to enhance a cell absorption ability and transfection efficiency of PNA. CONSTITUTION: A complex for PNA delivery contains negative charge oligo-aspartic acid(Asp)-PNA and a cationic carrier. The cationic carrier is polyethylene imine(PEI) or lipofectamine. The oligo-Asp is conjugated with PNA. The complex has Asp(n)-PNA-PEI wherein n is 5-12. The molecular weight of PEI is 20-30 kDa.
Placebo gel applied to skin once per day for 1 year. Starting dose 1.25mL per day. Dose randomly adjusted in 1.25mL increments for 1st 6 months of study after each study visit up to maximum of 5.0mL per day.
Certain embodiments of the present invention provide methods and systems for remote access to a healthcare information system from a diagnostic imaging modality scanner console. Certain embodiments provide a browser located at a diagnostic imaging system console and configured to access a healthcare information system from a diagnostic imaging system console. The browser includes a data connection between a healthcare information system and a diagnostic imaging system console. The browser also includes an interface enabling remote access to information at the healthcare information system from the diagnostic imaging system console. The interface is also configured to enable remote retrieve and modification of information at the healthcare information system. Information at the healthcare information system may include patient exam order information, for example. The healthcare information system may include a RIS or PACS, for example.
Total neointima implantation (patch neointima technique + triple-branched stent graft placement) has been performed in proximal aortic repair for acute type A aortic dissection (ATAAD) for more than 10 years at a center. However, there is no report on the mid-term outcomes with a control group of the surgical procedure. Consequently, the authors aimed to evaluate the safety and efficacy of this technique in this study. Patients who underwent the total neointima implantation were classified as Group A, and those who underwent the conventional aortic root reconstruction with the "sandwich" technique and the total aortic arch replacement were classified as Group B. Furthermore, the authors described the preoperative characteristics, operative data, and patient outcomes. Group A patients experienced a shorter surgery duration, lower volumes of perioperative bleeding, and fewer red blood cell transfusions. The incidence of neurological complications was significantly reduced in Group A. All patients maintained a normal range of proximal aortic sizes after surgery. Kaplan-Meier analysis revealed no significant differences between the patients in the two groups regarding cumulative mortality and the incidence of moderate-to-severe aortic insufficiency. In well-selected patients, total neointima implantation is an alternative procedure for the surgical repair of ATAAD.
The study has 2 stages: first stage would be survey of 400 employees, who will fill out a questionnaire to identify occupational and demographic risk factors, a nutritional questionnaire, and data from periodic checkups will be collected. Participants will sign a consent form for vitamin D level determinations, and for freezing blood samples. From this survey, the participants that have vitamin D deficiency (25(OH)D levels \< 20 ng/ml) will continue to the second stage of the study - administration of vitamin D or placebo. Participants in the interventional study will sign an additional consent form. Length of follow-up: one year. All parameters will be tested at 0, 6, and 12 months.
Symptomatic bradycardia occurred in patients treated with ALECENSA.

In the pooled safety population [see Adverse Reactions (6.1)], bradycardia occurred in 11% of patients treated with ALECENSA. Twenty percent of 521 patients treated with ALECENSA, for whom serial electrocardiograms (ECGs) were available, had post-dose heart rates of less than 50 beats per minute (bpm).

Monitor heart rate and blood pressure regularly. For asymptomatic bradycardia dose modification is not required. For symptomatic bradycardia that is not life-threatening, withhold ALECENSA until recovery to asymptomatic bradycardia or to a heart rate ≥ 60 bpm and evaluate concomitant medications known to cause bradycardia, as well as anti-hypertensive medications. If bradycardia is attributable to a concomitant medication, resume ALECENSA at a reduced dose (see Table 2) upon recovery to asymptomatic bradycardia or to a heart rate of ≥ 60 bpm, with frequent monitoring as clinically indicated.

Permanently discontinue ALECENSA in cases of life-threatening bradycardia if no contributing concomitant medication is identified [see Dosage and Administration (2.4)]. Permanently discontinue ALECENSA for recurrence of life-threatening bradycardia.
PROBLEM TO BE SOLVED: To obtain the subject composition capable of providing the suppository hardly causing increase of a melting point and having a strong structure by mixing a gelling agent with an oil and fat suppository substrate. SOLUTION: This composition is obtained by mixing (A) an oil and fat suppository substrate (for example, a cacao butter and a lauric fat solid at a normal temperature) with (B) a gelling agent (for example, a light quality anhydrous silicic acid and a fatty acid ester of dextrin). The formulating amount of the component B is preferably 1-10 wt.% based on the amount of the component A. When the component B is mixed with the component A by using the light quality anhydrous silicic acid as the component B, the mixing is carried out by heating and melting the component A, gradually adding the light quality anhydrous silicic acid thereto and homogeneously mixing the added product.  When the fatty acid ester of the dextrin is used as the component B, the mixing is carried out by previously heating and melting the component A, adding the fatty acid ester of the dextrin to the heated component A, homogeneously mixing the product, and heating the homogeneous product at 70 deg.C. Additionally, a medicine, e.g. steroid hormone and local anesthetic, can be formulated with the composition.
1,183,506. Influenza vaccines. RHONEPOULENC S.A. 20 Nov., 1967 [21 Nov., 1966], No. 52684/67. Heading A5B. Inactivated influenza virus suspensions are prepared by culturing the one or more strains of influenza virus in the allantoic cavity of an embryonated chicken egg, purifying the virus by differential centrifugation and inactivating it by treatment with diethyl ether or ethyl acetate at 0 to 5C. The purified and inactivated virus may be incorporated into vaccine preparations for administration to animals and humans by the oral, parenteral, rectal or nasal route including emulsified suspensions in animal or vegetable oils.
PURPOSE: To describe a case of replaced posterior cerebral artery (PCA) in which all branches of the PCA arose from the anterior choroidal artery (AChA) with an early branching temporal artery.
METHODS: An 83-year-old man with cerebral infarctions underwent cranial magnetic resonance (MR) imaging and MR angiography using a 3-Tesla scanner. MR angiography was performed using a standard 3-dimensional time-of-flight technique.
RESULTS: A large anomalous artery arose from the supraclinoid segment of the right internal carotid artery (ICA) and supplied all branches of the right PCA, mimicking fetal-type PCA. The temporal branch arose from the proximal segment of this artery. In MR angiographic source images, a tiny artery arose from the right ICA proximal to the origin of the anomalous artery, indicating a hypoplastic right posterior communicating artery (PCoA). Thus, we concluded that the anomalous artery was a replaced PCA; all branches of the PCA arose from the AChA.
CONCLUSION: We present a case involving a replaced PCA with an early branching temporal artery, as seen on MR angiography. Careful observation of MR angiographic source images is useful for identifying small arteries. To our knowledge, this is the first report of this combined variation in the relevant English-language literature.
PURPOSE:An anticancer drug prepared by using an aqueous solution of eosine yellowish as an injection. CONSTITUTION:An aqueous solution obtained by dissolving eosine yellowish (C20H6Br4Na2O5) as a main constituent into a physiological sodium chloride solution, a buffer solution, etc. is used as an injection. The direct injection of said aqueous solution into cancer tissues leads to the digestion of the cancer cells and consequently the reduction in the tissues. The eosine yellowish has low toxicity, e.g. the oral LD50 of 5.0g/kg in quineapigs.
A device receives an image. The image is applied to a sequence of encoders that includes a first encoder and one or more subsequent encoders, each including a U network encoder which performs convolution neural network processing. The one or more subsequent encoders receive a down-sampled version of the image from a prior encoder. The sequence of encoders form a first dimension orthogonal to the orthogonal dimension. A result of the sequence of encoders is applied to a sequence of decoders that includes a first decoder and one or more subsequent decoders. A respective decoder comprises a U network decoder that performs convolution neural network processing of an up-sampled version of the image from the first decoder. Probability outputs are produced from paired encoders and decoders in the sequence of encoders and the sequence of decoders. The probability outputs are combined to form a final output.
Sodium acetate is used for stabilizing alkali sulphates of natural conjugated esterogens (esp. when to be stored for long periods in the dry state) in a concn. of 0.5-50% (esp. 2-10%). Sodium acetate is physiologically innocuous, and its stabilising effect lasts for an unlimited time. In an example oestrogen sulphate sodium salts are stored at room temp. (23 degrees C) in the presence of 5% sodium acetate for 90 days. The percentage of the oestrogen sulphate sodium salt remaining undecomposed was, e.g. 100% for equilin, equilenin and alpha-oestradiol.
Post-mitotic, non-proliferative dermal fibroblasts have crucial functions in maintenance and restoration of tissue homeostasis. They are involved in essential processes such as wound healing, pigmentation and hair growth, but also tumor development and aging-associated diseases. These processes are energetically highly demanding and error prone when mitochondrial damage occurs. However, mitochondrial function in fibroblasts and the influence of mitochondrial dysfunction on fibroblast-specific demands are still unclear. To address these questions, we created a mouse model in which accelerated cell-specific mitochondrial DNA (mtDNA) damage accumulates. We crossed mice carrying a dominant-negative mutant of the mitochondrial replicative helicase Twinkle (RosaSTOP system) with mice that express fibroblast-specific Cre Recombinase (Collagen1A2 CreERT) which can be activated by Tamoxifen (TwinkleFIBRO). Thus, we are able to induce mtDNA deletions and duplications in specific cells, a process which resembles the physiological aging process in humans, where this damage accumulates in all tissues. Upon proliferation in vitro, Tamoxifen induced Twinkle fibroblasts deplete most of their mitochondrial DNA which, although not disturbing the stoichiometry of the respiratory chain complexes, leads to reduced ROS production and mitochondrial membrane potential as well as an anti-inflammatory and anti-fibrotic profile of the cells. In Sodium Azide treated wildtype fibroblasts, without a functioning respiratory chain, we observe the opposite, a rather pro-inflammatory and pro-fibrotic signature. Upon accumulation of mitochondrial DNA mutations in vivo the TwinkleFIBRO mice are protected from fibrosis development induced by intradermal Bleomycin injections. This is due to dampened differentiation of the dermal fibroblasts into α-smooth-muscle-actin positive myofibroblasts in TwinkleFIBRO mice. We thus provide evidence for striking differences of the impact that mtDNA mutations have in contrast to blunted mitochondrial function in dermal fibroblasts and skin homeostasis. These data contribute to improved understanding of mitochondrial function and dysfunction in skin and provide mechanistic insight into potential targets to treat skin fibrosis in the future.
Liver rupture repair surgery serves as one tool to treat liver rupture, especially beneficial for cases of mild liver rupture hemorrhage. Liver rupture can catalyze critical conditions such as hemorrhage and shock. Surgical workflow recognition in liver rupture repair surgery videos presents a significant task aimed at reducing surgical mistakes and enhancing the quality of surgeries conducted by surgeons. A liver rupture repair simulation surgical dataset is proposed in this paper which consists of 45 videos collaboratively completed by nine surgeons. Furthermore, an end-to-end SA-RLNet, a self attention-based recurrent convolutional neural network, is introduced in this paper. The self-attention mechanism is used to automatically identify the importance of input features in various instances and associate the relationships between input features. The accuracy of the surgical phase classification of the SA-RLNet approach is 90.6%. The present study demonstrates that the SA-RLNet approach shows strong generalization capabilities on the dataset. SA-RLNet has proved to be advantageous in capturing subtle variations between surgical phases. The application of surgical workflow recognition has promising feasibility in liver rupture repair surgery.
Part B: A controlled, prospective, randomized, double-masked study in which up to 30 subjects meeting eligibility criteria will be randomly assigned in a 1:1 ratio to receive a single ITV injection of2.0 mg/eye VEGF Trap (or the MTD if reached prior to 2.0 mg) followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later. Enrollment into Part B will begin 2 weeks after the last subject to receive the 2.0 mg/eye dose in Part A has been observed for 15 days and it has been determined that the safety profile of VEGF Trap at this dose level is adequate to support expansion of dosing at this dose level. The dose of pegaptanib sodium will be 0.3 mg, according to the package insert.
The invention provides a divalent double-core platinum complex represented as the formula I or the formula II. The preparation method comprises following steps: taking diethylene triaminepentaacetic acid (DTPA) as the ligand, and forming the target product through coordination of two symmetrical pairs of carboxyl groups of DTPA and cisplatin. The divalent double-core platinum complex has a stable bi-center octagon structure. The divalent double-core complex with the structure mentioned above exists in a carboxylate form under the physiology conditions, is very easy to dissolve, can resist the absorption of proteins in human bodies at the same time, therefore the circulation time of platinum in the blood is prolonged, and the enrichment of platinum in the tumor tissues is promoted. In the low pH environment of the tumor tissue, compounds with antitumor activity can be slowly released from the carboxylic acid divalent double-core platinum complex, and therefore the goals of reduction on physical toxicity of the cisplatin original medicine and maintenance of antitumor activity are achieved. Furthermore, the DTPA is taken as the ligand in the preparation method, and the safety is high.
To examine whether patterns, such as the timings of onset or recovery from sleep disturbance, are associated with later developmental problems, including autism spectrum disorder (ASD). Mothers participating in the Japan Environment and Children's Study with a child aged 3 years were included in the analyses. Children were assessed for short sleep and frequent awakenings at 1 month, 6 months, and 1 year of age. Developmental problems were evaluated at 3 years of age based on ASD diagnosis and developmental delay, using the Japanese translation of the Ages and Stages Questionnaire (ASQ) 3rd edition. Sleep disturbance patterns were classified by onset age, and developmental problem risks were examined based on onset/recovery ages. Among 63,418 mother-infant dyads, 0.4% of infants were later diagnosed with ASD, and 14.4% had abnormal scores on any ASQ domains. The later the onset of short sleep, the lower the risk of abnormal ASQ scores (RR of short sleep onset at 1 year: 1.41; 6 months: 1.52; 1 month: 1.57). The earlier the infants recovered from short sleep persistence, the lower the risk of developmental delay (RR of remittance of sleep problems identified at 1 month by 6 months: 1.07; 1 year: 1.31; not before 1 year: 1.57). Although not all patterns were significant, later short sleep onset and earlier recovery were associated with lower ASD risk. These findings may have significant implications for future interventions in infant development.
Blood lipid management is a key approach in the prevention of chronic kidney disease (CKD). Remnant cholesterol (RC) plays an important role in the development of multiple diseases via chronic inflammation. The aim of our study was to determine the relationship between RC and CKD and explore the role of inflammation in this relationship. The 7696 subjects from the Chinese Health and Nutrition Survey were divided into four subgroups according to the quartile of RC. The estimated glomerular filtration rate was calculated using the CKD Epidemiology Collaboration equation. Fasting RC was calculated as total cholesterol minus low-density lipoprotein cholesterol and high-density lipoprotein cholesterol. Logistic regression analysis was employed to evaluate the relationships between RC and CKD. Mediation analysis was undertaken to identify potential mediators of high-sensitivity C-reactive protein (hs-CRP) and white blood cells (WBCs). Of all participants, the mean age was 51 years, and the male accounted for 47.8%. The multivariable-adjusted odds ratios (95% CIs) for the highest versus lowest quartile of remnant cholesterol were 1.40 (1.10-1.78, p for trend = 0.006) for CKD. RC and preinflammatory markers have combined effect on CKD. The preinflammatory state, presented by increased hs-CRP or WBCs, partially mediated the association between RC and CKD with proportion of 10.14% (p = 0.002) and 11.65% (p = 0.012), respectively. In conclusion, this study suggested a positive relationship between RC and CKD, which was partially mediated by preinflammatory state. These findings highlight the importance of RC and inflammation in renal dysfunction.IMPACT STATEMENTWhat is already known on this subject?: Dyslipidemia plays an important role in the development of chronic kidney disease (CKD). Remnant cholesterol (RC), as a triglyceride-rich particle, can contribute to target organ damage, primarily through inflammatory pathways. However, the relationship between RC and CKD in the community-dwelling population, particularly the role of inflammation, is not yet fully understood.What do the results of this study add?: This study shows that RC was significantly associated with CKD. RC and preinflammatory status exhibit a combined effect on CKD. Preinflammatory state, presented by increased high-sensitivity C-reactive protein or white blood cells, partially mediated the association between RC and CKD.What are the implications of these findings for clinical practice and/or further research?: The study provides us with a better understanding of the role of RC and inflammation in kidney dysfunction and raises the awareness of RC in the management of CKD.
OBJECTIVE: The aim of this study was to evaluate the morbidity associated with microsurgical treatment in patients with a recurrent aneurysm to improve their surgical management.
METHODS: From 2012 to 2022, among the 3128 patients with ruptured or unruptured intracranial aneurysms managed at the authors' institution, 954 patients were treated by a microsurgical procedure. Of these 3128 patients, 60 consecutive patients (6.3%) who had a recurrent microsurgically treated aneurysm after previous endovascular treatment were included in this study. Additional microsurgical treatment was considered in case of progressive remnant growth or significant aneurysm recurrence. Intraoperative and postoperative complications were noted. Early (< 7 days) and long-term clinical and radiological monitoring were performed. Good functional outcome was considered as a modified Rankin Scale score < 3.
RESULTS: The mean age at initial treatment was 45 years (range 26-65 years). The mean delay between the first treatment and microsurgical treatment of the recurrence was 64 months (range 2 days-296 months). The mean size of the fundus recurrence was 5 mm, and the mean size of the neck recurrence was 4.6 mm. Five patients (8.3%) presented with subarachnoid hemorrhage associated with rupture of the recurrent aneurysm. Three patients died (6%) of aneurysm rupture and/or intensive care complications. The total morbidity rate associated with the microsurgical procedure was 14.5% (8/55) in patients with unruptured recurrent aneurysms. Among these patients, postoperative definitive complications (ischemic lesions) directly related to the microsurgical procedure were present in 3 patients (5.5%). Intraoperative rupture was recorded in these 3 patients. In the 54 surviving patients with unruptured recurrent aneurysms, good functional outcome was noted in 49 (91%). Poor functional outcome was significantly associated with intraoperative rupture.
CONCLUSIONS: Microsurgery remains an effective therapeutic option for recurrent intracranial aneurysms. However, in the authors' experience, postoperative morbidity is higher than in patients with nonrecurrent aneurysms. Therefore, a pretherapeutic multidisciplinary evaluation is mandatory to reduce the potential morbidity associated with the retreatment as much as possible. When endovascular occlusion of the aneurysm requires both stenting and coiling, alternative microsurgical treatment should be carefully evaluated, as microsurgical clipping will become much more challenging in cases of aneurysm recurrence.
Placebo will consist of microcrystalline cellulose. Two placebo capsules will be administered per day starting week 1 day 3 through the end of the isradipine taper.
PURPOSE:To obtain granules having voids in the interior, capable of floating in a medium in a wide pH range, by dispersing a chitosan and a weakly acidic solution of main drug into an inert medium and adding a weak alkali to the prepared dispersion. CONSTITUTION:A chitosan, preferably one having low deacetylation degree and a weakly acidic solution of an orally administrable drug are dispersed into an inert medium (e.g. liquid paraffin) to give a dispersion, to which a weak alkali is added to give granules. The granules are collected. The granules immediately float in purified water in vitro and in the stomach, sustained release is observed and degree thereof enlarges with increase of concentration of chitosan. Moreover, durable absorption of the main drug is observed in an examination in vivo using a dog. Sustained release of the granules can be further controlled by laminating a chitosan to the granules.